# Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

> **NCT07161843** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Ebima Clifford Okundaye** · enrollment: 500 (estimated)

## Conditions studied

- Acute Renal Failure (ARF)
- Acute Tubular Necrosis

## Interventions

- **DRUG:** QRX-3

## Key facts

- **NCT ID:** NCT07161843
- **Lead sponsor:** Ebima Clifford Okundaye
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-02-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07161843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07161843, "Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07161843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*